Nate Wilson

I’ve been bad at keeping up with posting during fellowship, but excited to announce that I will be starting my post-training career as a melanoma medical oncologist @WinshipAtEmory next week. So grateful for my mentors, support system, and very excited for this next chapter!

🚨Hot off the press: A simultaneous publication in @JCOOP_ASCO alongside @vpatelmd’s presentation highlighting the 1st cluster randomized study evaluating podcasts for heme/onc education! The outcome: @TheFellowOnCall and @TwoOncDocs should be included for h/o fellow education!

Always a great time at UM ASCO reception!

BRIDGING GU ONCOLOGY & INTERNAL MEDICINE - @OAlhalabiMD #NupurKikaniMD @MDAndersonNews Led with star colleague @Nate_WilsonMD (Ex-Chief @UTHimres), we share an ORIGINAL report on mgt of systemic toxicity of an ADC that changed bladder cancer care 🔗shorturl.at/7Nrhz👇1/

⚡️NOW in @jitcancer👉Nivo/ipi in metastatic variant histology renal cell carcinoma 👇Mentored by kidney cancer legend #NizarTannirMD & @OAlhalabiMD, happy to share our experience @MDAndersonNews co-led w/ terrific friends @Nate_WilsonMD & Jaanki! 🔗bit.ly/3QFrzON🧵1/

Congrats @Nate_WilsonMD on this well written piece! Neoadjuvant treatment in advanced resectable melanoma and the need for a predictive biomarker - is pathologic complete response (pCR) the answer? - The American Journal of Surgery americanjournalofsurgery.com/article/S0002-… @UMHemOncFellows

🔥 OUR LATEST #OriginalResearch in @CancerMedicineJ on Small Cell Neuroendocrine Carcinoma of the Urinary Tract (SCNEC-URO)👉What drives post-surgical relapse in this aggressive disease? @OAlhalabiMD @DocMattCampbell @MDAndersonNews 🔗bit.ly/3E3R7lJ A thread🧵1/

END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO @ProfCUBlankNKI nejm.org/doi/full/10.10…

Hot off the press. Excited to share work done by stellar @UroOnc fellow @AmandaMyersMD mentored by @UroDocAsh Further advancing knowledge on aggressive #bladdercancer subtypes. T1 nonmuscle invasive small cell neuroendocrine carcinoma 🔗 sciencedirect.com/science/articl…

👉👉👉Thanks 🙏 🙏 🙏 to @umichmedicine Div HemOnc for hosting me for Grand Rounds visiting Professor talk and visit ! @Nate_WilsonMD @KMirza @acweyand @kristenpettitmd @Berninini 🙌 #BPDCN #MPNSM #RareDisease #leusm

Strong UM Fellow representation at the annual MSHO conference!

👋This is Mohammad Jad, Postdoc. Fellow & Postdoc. Association Team Leader @MDAndersonNews, mentored by @DocMattCampbell & @OAlhalabiMD 👉Applying for #InternalMedicine Residency #Match2025 🙏Dreaming of becoming a humane #oncologist through purposeful science – excited to find the right #IM program to make this dream a reality! AAMC ID: 15705243 #IMG

Dermatology: important diagnosis

Great #MultiDisciplinary work led by #MDAPulmonary @sotofelipe26 @ajaysheshadri Lydia Glick @BCM_InternalMed @Nate_WilsonMD @UTHimres @PalaskasN @MehmetAltanMD on #LungCancer #ICIs #ILAs @MDAndersonNews clinical-lung-cancer.com/article/S1525-…

The Cancer-Immunity Cycle By Ira Mellman & colleagues in @ImmunityCP 2013: cell.com/immunity/fullt… 2023 update: cell.com/immunity/fullt… (L) 2013 (R) 2023 The underlying concepts have been the capstone for a lot of modern day cancer immunotherapy research.

Important work led by rising ⭐️ @sotofelipe26 and mentors @MehmetAltanMD @ajaysheshadri to better understand outcomes for patients with NSCLC who have developed ICI-related pneumonitis sciencedirect.com/science/articl…

Very grateful for my experience attending the @AACR-@ASCO Methods in Clinical Cancer Research Workshop in La Jolla. Humbling to be surrounded by such incredible people, ideas, current and future leaders in this field

DOR to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation @drenriquegrande @mjmoussa_ @Nate_WilsonMD @VivekSubbiah @DocMattCampbell @PavlosMsaouel @OAlhalabiMD oncodaily.com/blog/107634.ht… #Cancer #BladderCancer #CancerResearch #OncoDaily #Oncology

Amazing time at the lake house celebrating the arrival of our new first year fellows and beginning of the new academic year!

⚡️NOW IN PRESS: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy🧬 #PrecisionOncology 👉GU ASCO #GU24: Original multi-institutional series on off-label use of lurbi in SCBC-enriched GU cohorts @OAlhalabiMD @Parminder1699 @AlanBryce9 👉#ASCO24: Phase II LASER study announcement (lurbi +/- avelumab)🌟@SaadAtiq24 @apolo_andrea 👉Now: Our structured #report @CurrentOncology with a hypothesis-testing paradigm, awaiting objective response 🔗 mdpi.com/1718-7729/31/6…